TNXP: Rasio rega marang prakiraan pendapatan Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals (TNXP) relies on alliances with scientific centers to develop vaccines and pain management treatments. The projected price-to-sales ratio visualizes these expectations, with the metric currently standing at 1.30. The company is currently allocating funds toward R&D in anticipation of excess profits from its patents. To outperform numerous peers in the sector, the firm is rapidly accelerating its development pipeline.
Tonix Pharmaceuticals Holding Corp. - rincian analitis lan metrik utama (TNXP)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas Tonix Pharmaceuticals|TNXP - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Tonix Pharmaceuticals Holding Corp.|TNXP - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Tonix Pharmaceuticals|TNXP - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Tonix Pharmaceuticals|Rasio cepet tonixpharma.com
- data bathi bisnis lan rasio investasi:
TNXP - Bathi resik|Bathi sing dikarepake Tonix Pharmaceuticals|TNXP - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep tonixpharma.com|TNXP - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Tonix Pharmaceuticals|TNXP - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Tonix Pharmaceuticals|TNXP - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan tonixpharma.com|TNXP - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Tonix Pharmaceuticals
- indikator dodolan lan pendapatan:
Ringkesan analisis perusahaan:TNXP (Tonix Pharmaceuticals Holding Corp.)
Forward P/S compares current market capitalization with expected revenue based on analyst forecasts, determining the extent of the premium paid for future cash flows. By analyzing the history of the forward P/S valuation, an investor can identify the risks of overvaluation for Tonix Pharmaceuticals (TNXP), whose financial stability depends critically on external funding due to the lack of stable revenue during the drug development stage.
Pesaing langsung
Multiplikator Forward P/S HLN (Haleon PLC)|Multiplikator Forward P/S Kenvue Corp KVUE|Verona Pharma PLC - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep jyongbio.com|LGND: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan AMRX|Rasio rega marang prakiraan pendapatan Perrigo Company|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alvotech ALVO|Multiplikator Forward P/S LQDA|GLPG: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake MannKind Corp (MNKD)|AMPH: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TBPH|AQST (Aquestive Corp) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan scPharmaceuticals Inc. (SCPH)|Multiplikator forward rega marang pendapatan TECX (Tectonic Therapeutic, Inc.)|SXTC (SXT Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S EPRX (Eupraxia Pharmaceuticals)|Rega forward marang dodolan BHST|Invizyne Technologies - Multiplikator Forward P/S|oramed.com (ORMP) - Multiplikator forward rega marang pendapatan|ENTX (enterabio.com) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Multiplikator Forward P/S|Multiplikator Forward P/S cumberlandpharma.com|Rasio rega marang prakiraan pendapatan Quantum BioPharma (QNTM)|FibroGen (FGEN) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S TELO (telomirpharma.com)|RANI - Multiplikator forward rega marang pendapatan|SNYR - Rasio rega marang prakiraan pendapatan|rallybio.com - Rasio rega marang pendapatan sing dikarepake|LEXX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pulmatrix Inc|PTHL (Pheton Holdings) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Aptorum Group Limited APM|Rasio rega marang prakiraan pendapatan Lyra Therapeutics (LYRA)|Multiplikator forward rega marang pendapatan Impact BioMedical Inc IBO|Rasio rega marang prakiraan pendapatan tnfpharma.com TNFA|Rega forward marang dodolan YCBD|PainReform Ltd - Multiplikator Forward P/S|Altamira Therapeutics Ltd (CYTO) - Multiplikator forward rega marang pendapatan|lipella.com (LIPO) - Rasio rega marang prakiraan pendapatan|OptiNose (OPTN) - Multiplikator Forward P/S|PIRS (Pieris Pharmaceuticals Inc) - Multiplikator Forward P/S|PROC: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|Multiplikator Forward P/S Qilian International Corp (QLI)|ACELYRIN, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S tffpharma.com TFFP
